Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-007: MK-1084 plus MK-3475A versus MK-3475A plus pemetrexed/platinum in first-line KRAS G12C-mutant nonsquamous NSCLC
2024-514500-14-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 33
01
Overview
Phase 3, randomised, open-label trial of calderasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival in participants with PD-L1 TPS at least 1%. Planned start Dec 2025; status: authorised.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514500-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514500-14-00.